GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » Float Percentage Of Total Shares Outstanding

Divi's Laboratories (NSE:DIVISLAB) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 13, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Divi's Laboratories's float shares is 0.00 Mil. Divi's Laboratories's total shares outstanding is 265.47 Mil. Divi's Laboratories's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Divi's Laboratories's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Divi's Laboratories's Institutional Ownership is 24.15%.


Divi's Laboratories Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Divi's Laboratories's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/265.47
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories (NSE:DIVISLAB) Business Description

Industry
Traded in Other Exchanges
Address
Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines